Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: J Health Psychol. 2020 Jun 9;26(14):2730–2742. doi: 10.1177/1359105320926526

Feasibility, acceptability, and preliminary impact of telemedicine-administered cognitive behavioral therapy for adherence and depression among African American women living with HIV in the rural South

Anna Junkins 1, Christina Psaros 2,3, Corilyn Ott 1, Andres Azuero 1, Crystal Chapman Lambert 1, Karen Cropsey 1, Robert Savage 1, Jessica E Haberer 2,3, Steven A Safren 4, Mirjam-Colette Kempf 1
PMCID: PMC8012083  NIHMSID: NIHMS1682152  PMID: 32515245

Abstract

Women living with HIV are disproportionally affected by depression and mental healthcare access. A pilot feasibility trial using videoconferencing compared cognitive behavioral therapy for antiretroviral therapy adherence and depression (N = 11) to supportive psychotherapy (N = 11). Participants completed 10–12 weekly therapy sessions and 6-month follow-up. Retention at 6 months was 95 percent. Depression symptoms significantly decreased in both arms; antiretroviral therapy adherence remained high as measured via self-report and Wisepill. Satisfaction with intervention components was high; videoconferencing was highly acceptable and comparable to face-to-face counseling. This study demonstrates the feasibility of telemedicine-administered psychotherapy addressing mental health needs among women living with HIV.

Keywords: adherence, cognitive behavioral therapy, depression, HIV, women’s health

Introduction

People living with HIV (PLWH) are disproportionately burdened by depression. Previous studies have estimated prevalence rates for depression among PLWH at 40 percent (Nanni et al., 2015; Pence et al., 2006). Thus, prevalence rates for PLWH are 2–3 times higher when compared to HIV-uninfected populations (Bing et al., 2001; Nanni et al., 2015). Gender differences in depressive symptoms have been documented in the literature with higher rates among women living with HIV (WLWH) when compared to men living with HIV and HIV-uninfected women (Do et al., 2014; Rabkin, 2008; Robertson et al., 2014).

Among PLWH, depressive symptoms have been associated with increased risk of mortality (Bouhnik et al., 2005; Cook et al., 2004; Farinpour et al., 2003), worsening HIV clinical progression (Bouhnik et al., 2005; Farinpour et al., 2003), and poor quality of life (Andrinopoulos et al., 2011; Vyavaharkar et al., 2012). Independent of its debilitating effects on health outcomes and quality of life, depression negatively impacts antiretroviral therapy (ART) and scheduled clinic visit adherence among PLWH. It has been recognized that depression is one of the strongest predictors of suboptimal adherence to ART and engagement in care (Ammassari et al., 2004; Bhatia et al., 2011; Bouhnik et al., 2005; Carrieri et al., 2006; Catz et al., 2000; Cook et al., 2004; Dalessandro et al., 2007; Gonzalez et al., 2011; Mugavero et al., 2006; Murphy et al., 2001; Paterson et al., 2000; Roberts and Mann, 2000; Turner et al., 2003). Patients who are depressed attend fewer scheduled clinic visits than patients who are not depressed (Schumacher et al., 2013).

African American (AA) women living in the Deep South (i.e. Alabama, Georgia, Louisiana, Mississippi, North Carolina, and South Carolina) are disproportionately impacted by HIV with incidence rates comparable to rates among women in sub-Saharan Africa (Hodder et al., 2013). About 70 percent of all HIV diagnoses among women in the South are among AA women (CDC, 2014). In addition, prevalence of depression among adults is highest among AA women compared to White and Hispanic men, and White and Hispanic women (Brody et al., 2018). Depression is more prevalent in the Deep South compared to other states, with women and AAs being more likely to be depressed than their male and White counterparts (CDC, 2010).

Despite the substantial burden of comorbid depression, there is a lack of interventions addressing the unique concerns associated with depression among WLWH (Sherr et al., 2011) and little is known about effective intervention strategies and modes of intervention delivery that address WLWH’s barriers to retention and adherence to care (Reif et al., 2006). Given that WLWH are more likely to live in rural areas of the United States where access to diverse healthcare services are limited, intervention strategies addressing depression co-morbidity as a means to increase adherence to care will have to use non-traditional modes of healthcare delivery.

Telemedicine has been found to help overcome barriers of provider shortage, especially in rural areas where access to specialty care, particularly psychiatric care, is greatly limited and often nonexistent (Benavides-Vaello et al., 2013). Studies among primary care providers and patients alike have indicated high acceptability of telemedicine-administered mental health services, including treatment for depression, especially in rural areas (Rohland, 2001; Swinton et al., 2009). Telemedicine-delivered cognitive behavioral therapy (CBT) has been shown to improve depression and anxiety among diverse populations such as pregnant and post-partum women, college students, and patients with Parkinson’s disease (Davies et al., 2014; Dobkin et al., 2018; Nair et al., 2018). In addition, telemedicine has been successful in providing care in other settings such as psychotherapy among older veterans, specialty endocrinology care among patients with Type 1 diabetes, and telenursing for patients at their homes (Egede et al., 2015; Gidora et al., 2019; Lorentz, 2008; Xu et al., 2018). Videoconferencing as a modality of telemedicine has been largely understudied, but in some small studies, has been shown to be comparable to telephone use among patients and providers (Rush et al., 2018).

Telemedicine-distributed interventions can help to overcome structural barriers of access to mental healthcare while providing expertly delivered specialty care. However, telemedicine-administered mental health interventions addressing the needs of WLWH and chronically ill patients in the United States, who are struggling with access to mental healthcare, are missing at large. The objective of this pilot study was to test the feasibility and acceptability of a telemedicine-administered, culturally adapted CBT for depression and antiretroviral therapy adherence (CBT-AD) approach (Safren et al., 2009) using videoconferencing among AA WLWH in the rural South.

Method

Study design

A time-matched pilot randomized controlled trial (RCT) was implemented among WLWH receiving HIV care across Alabama. Participants were randomly assigned to the CBT-AD intervention or supportive psychotherapy, both of which were administered through videoconferencing. A mixed-methods study design was used to collect information regarding acceptability and feasibility of utilizing videoconferencing telemedicine for counseling sessions. Data collection from individual interviews allowed for a deeper understanding of how WLWH in the Deep South accepted the interventions and use of telemedicine for their counseling needs.

Study sample

The study sample included WLWH seeking care at four HIV care outpatient clinics in Alabama between 2014 and 2016. Inclusion criteria required that the participants be female, AA, age 19 years or older, HIV-positive, English-speaking, seeking care at one of the clinics, on ART for at least 2 months, and have a diagnosis of depression. Exclusion criteria included substance abuse that would interfere with therapy, a mental health disorder determined by the Mini International Neuropsychiatric Inventory (MINI) other than depression that would interfere with therapy, and CBT treatment within the last 12 months. This study was approved by the University of Alabama at Birmingham Institutional Review Board (IRB # F120315002).

Procedure

Participating clinics referred potential participants based on their meeting preliminary inclusion criteria. Each referred participant received a call from study staff to further determine eligibility for the study. At the baseline visit, after verbal consent was obtained, participants were given the Center for Epidemiological Studies Depression Scale (CES-D; Radloff, 1977) to assess depression symptoms. The MINI was administered by a trained psychologist to confirm their eligibility based on a confirmed depression diagnosis. In addition to completing the baseline assessment battery (i.e. demographic and psychosocial assessments), participants received instructions on using the Wisepill device, an electronic adherence monitoring (EAM) device (Stringer et al., 2019). After baseline visits, the study team met to discuss the eligibility of each participant based on exclusion criteria.

Following the baseline visit, 22 qualified participants were randomized to either the CBT-AD intervention or supportive psychotherapy. Participants received between 10 and 12 weekly 1-hour telemedicine sessions with a clinical psychologist in training (female doctoral students with prior training in CBT) supervised by certified psychologists and psychiatrists. These sessions took place within a private room located at the participant’s clinic. Participants in both conditions spent time in the sessions reviewing adherence to ART and use of the Wisepill device over the previous 2 weeks. After the completion of the weekly sessions, participants returned for follow-up visits scheduled at 13 weeks immediately following treatment and 24 weeks. The MINI was re-administered at the follow-up visits. All sessions were audio-recorded. Participants were monetarily reimbursed for their time and travel.

Intervention

The control condition participated in information and supportive psychotherapy (ISP) which integrated the Life Steps (Safren et al., 1999) cognitive-behavioral adherence counseling approach in up to two sessions at the beginning of the intervention. Life Steps was used to help solve potential problems associated with medication adherence, and included the following: getting to appointments, communication with the treatment team, coping with medication side effects, obtaining and storing medications, formulating a daily medication schedule, and cuecontrol strategies for taking medications. Participants were introduced to each step, identified potential barriers to the step, and made a plan and backup plan.

The CBT-AD condition sessions focused on: (1) Life Steps; (2) motivational interviewing exercises to address pros and cons of improving depression and HIV care adherence; (3) behavioral activation designed to increase activities that involve pleasure and mastery; (4) cognitive restructuring, with special attention given to negative automatic thoughts that are related to HIV care adherence; (5) problem-solving, with development of an action plan targeting problems that contribute to depression as well as barriers to HIV care adherence; and (6) relaxation training (teaching of muscle relaxation and diaphragmatic breathing skills). The CBT-AD intervention content was adapted for the study population to include culturally appropriate examples and language to reflect life experiences and context among AA women.

Outcomes

The main outcomes of the study were feasibility and acceptability of the intervention and its delivery. Several measures were used to quantitatively and qualitatively assess acceptability and feasibility of the intervention. The Client Satisfaction Questionnaire (CSQ-8; Attkisson, 1982) was used to assess satisfaction with treatment. The eight items on the CSQ-8 are given a rating from “1” indicating the most negative response to “4” indicating the most positive response. For example, one question asks: “How would you rate the quality of service you have received?” with the participant rating the treatment from “1” indicating “Poor” and “4” indicating “Excellent.” The total score ranges from 8 to 32.

In addition, acceptability and feasibility of the counseling sessions, adherence counseling, the Wisepill device, and Telemedicine were assessed using an adapted scale (Vandelanotte and De Bourdeaudhuji, 2003). For each intervention component, there were 4–10 questions which participants marked a response ranging from “1” indicating the most negative rating to “5” indicating the most positive rating. For example, one states: “Using Telemedicine for your counseling sessions was helpful” with participants ratings from “1” indicating “Completely Disagree” to “5” indicating “Completely Agree.” The total scores ranged from 20 to 100.

Exit in-depth interviews were conducted to qualitatively explore acceptability of the intervention and delivery among the participants. Participants were asked questions such as “What did you think was the most helpful part of your counseling experience?”; “ What were barriers that made it difficult to complete your counseling sessions?”; and “What was your experience with the Wisepill device?” Probes were used in the interview to collect more information about the participants’ experience. In addition to the measures described above, feasibility was assessed by intervention completion.

Preliminary impact on depressive symptoms was assessed using the CES-D. Viral load suppression (<200 copies/ml), the AIDS Clinical Trial Group (ACTG) ART adherence survey (Chesney et al., 2000), and the Wisepill device were used to evaluate ART adherence. With regards to the ACTG ART adherence survey, participants were considered adherent if they reported not missing a dose of medication within the previous 2 weeks, as per the following question: “When was the last time you missed taking any of your medications?” Raw Wisepill data were adjusted for technical problems and self-reported behaviors such as taking out several doses of medication at a time.

Statistical analysis

Demographic and clinical characteristics, feasibility and acceptability ratings, and depression and adherence outcomes were compared between participants receiving CBT-AD and ISP at baseline, 13, and 24 weeks. Mean values and standard deviations (SD) were computed from raw data and effect sizes (ESs) were computed from model estimates. Cohen’s (1988) d ESs were calculated for numerical variables, using pooled baseline SD and d-equivalent for binary variables (Rosenthal and Rubin, 2003). Because this was a pilot study, statistical inference was not conducted as the sample size was too small (Leon et al., 2011). Therefore, results apply to the specific sample and no generalization beyond the sample is claimed.

Exit interviews were audio-recorded and transcribed. De-identified transcripts were analyzed by two investigators independently using line-by-line open coding. The analysists then met and agreed upon any differences in the thematic analyses. Qualitative analyses were conducted using NVivo 10 (Castleberry, 2014).

Results

Potential participants (N = 60) were referred by participating clinics based on meeting preliminary inclusion criteria (Figure 1). During screening for meeting enrollment criteria, it was determined that eight participants did not screen positive for depression on the CES-D short form (score ⩽ 10), five participants were not currently on ART, and three participants chose not to participate. The remaining participants (N = 44) were asked to participate in a baseline assessment via videoconferencing to further determine eligibility. A total of 21 participants did not proceed to the randomized portion of the study for the following reasons: lack of depression diagnosis per the MINI, previously received CBT, substance abuse or mental illness that would interfere with the intervention, and self-withdrawal. An additional participant withdrew from the study after randomization but before beginning intervention sessions. The remaining participants (N = 22) were enrolled and randomized to either CBT-AD (N = 11) or ISP (N = 11).

Figure 1.

Figure 1.

Consort diagram of study participant enrollment, randomization, and follow-up.

CBT-AD: cognitive behavioral therapy for antiretroviral therapy adherence and depression; ISP: information and supportive psychotherapy.

Participant characteristics

Demographic and clinical characteristics of the participants are displayed in Table 1. On average, participants receiving CBT-AD and ISP were 48 and 43 years old, respectively. Overall, approximately 41 percent of participants were separated, divorced, or widowed; 32 percent were married or with a partner; and 27 percent were single. About 14 percent of participants were college graduates, 41 percent attended some college or technical training, 27 percent of participants’ highest level of education achieved was high school graduation or general educational development (GED), and 18 percent had less than a high school education. Slightly over half (54%) of the participants had an income of less than US$10,000 within the last year. The majority (68%) of participants had been diagnosed with depression prior to the study. On average, participants were diagnosed with HIV 8 years prior and had initiated ART 6.5 years prior to study enrollment. Two participants were immunosuppressed (CD4 count <200 cells/μl), and most participants (86%) were virally suppressed (<200 copies/ml) at baseline.

Table 1.

Demographic and clinical characteristics of study participants.

Overall (N = 22) CBT (N = 11) ISP (N = 11) Effect sizea
Age (years), mean (SD) 45.8 (± 11.8) 48.6 (± 11.3) 43 (± 12) 0.47
Marital status, N (%) 0.88
 Single 6 (27.3) 5 (45.5) 1 (9.1)
 Married/partnered 7 (31.8) 1 (9.1) 6 (54.5)
 Separated/divorced/widowed 9 (40.9) 5 (45.5) 4 (36.4)
Education, N (%) 0.77
 <High school 4 (18.2) 1 (9.1) 3 (27.3)
 High school graduate/GED 6 (27.3) 3 (27.3) 3 (27.3)
 Some college/technical training 9 (40.9) 7 (63.6) 2 (18.2)
 College graduate 3 (13.6) 0 3 (27.3)
Income within the previous year < US$10,000, N (%) 12 (54.5) 6 (54.5) 6 (54.5) 0.00
Ever diagnosed with depression, N (%) 15 (68.2) 9 (81.8) 6 (54.5) 0.40
Years since HIV diagnosis, mean (SD) 8.1 (7) 9.3 (8.2) 6.9 (5.7) 0.34
Years since ART initiation, mean (SD) 6.5 (5.7) 6.4 (5.8) 6.7 (5.8) 0.05
Immunosuppressed (CD4 count < 200 cells/μl), N (%) 2 (9.1) 1 (9.1) 1 (9.1) 0.00
Virally suppressed (HIV RNA < 200 copies/ml), N (%) 19 (86.4) 10 (90.9) 9 (81.8) 0.44

CBT: cognitive behavioral therapy; ISP: information and supportive psychotherapy; GED: general educational development; ART: antiretroviral therapy.

a

Cohen’s d for numerical variables, and d-equivalent for categorical variables.

Feasibility

All participants completed at least nine sessions. About 83% of participants (11 of 11 CBT-AD and 9 of 11 ISP) completed the 3-month follow-up visit. Two participants who did not complete the 3-month follow-up in ISP returned to complete the 6-month follow-up. Overall, 95 percent (21 of 22) randomized participants completed the 6-month follow-up visit. Participants completed an average of 11.5 weeks of intervention sessions, with an average duration of 14.7 weeks (see Table 2).

Table 2.

Feasibility and acceptability of intervention components.

Overall (N = 22) CBT (N = 11) ISP (N = 11) Effect sizea
Weeks of intervention, mean (SD) 11.5 (±1) 11.6 (±0.7) 11.3 (±1.2) 0.26
Weeks to complete intervention, mean (SD) 14.7 (±4.3) 13 (±2.7) 16.3 (±5) 0.77
Client satisfaction score (8–32), mean (SD) 30.8 (±3.7) 29.8 (±5)b 31.8 (±0.4)b 0.04
Acceptability ratings (20–100), mean (SD)
 Depression counseling 97.2 (±5.4) 96.4 (±7) 98 (±3.1) 0.30
 HIV treatment adherence counseling 96.6 (±12.8) 94.7 (±17.6) 98.5 (±5) 0.30
 Telemedicine 85.1 (±13.5) 83 (±17.3) 87.5 (±7.8)b 0.33

CBT: cognitive behavioral therapy; ISP: information and supportive psychotherapy.

Percentages vary depending on the total number of participants who completed the assessment.

a

Cohen’s d for numerical variables, and d-equivalent for categorical variables.

b

N = 10.

Acceptability

Participants rated their overall satisfaction as very high; the average CSQ-8 score was 30.8 of a maximum score of 32, indicating very high satisfaction and acceptability of the intervention. Acceptability ratings of the individual intervention components were also very high. Of 100 total points, on average, participants rated depression counseling at 97.2, HIV treatment adherence counseling at 96.6, and telemedicine use at 85.1.

Exit in-depth interviews qualitatively described the acceptability of the intervention among the participants. Positive comments about the Wisepill device included that it helped with accountability, made taking pills easier, helped to have a set schedule to take pills, and aiding as a visual reminder to take pills. A total of 18 participants indicated that the use of the Wisepill device was a positive experience for them. Detailed assessments of the Wisepill device are described elsewhere (Stringer et al., 2019).

Positive feedback from the participants regarding CBT-AD included that they felt they were able to open up with their counselor, felt stronger after completing their sessions, sessions helped them to clarify their life struggles, and that it provided them with tools they used after the sessions ended. Participants reported high satisfaction with their counselors independent of demographic profile of the counselor. One participant described the positive impact of CBT-AD in her life:

For that little brief moment, it kinda made me felt more, like gettin’ up and goin’ to work every day. It gave me somethin’ to look forward to. It really did. It wasn’t stressful. It made it good.

Another participant commented:

If I had a friend and a person that’s in my situation, I would tell them you owe it all to see the person I went to see because they helped me a great, great deal. It’s just somethin’ I would recommend a person to come and see you guys cuz you guys are wonderful. I mean, you know exactly what you’re doin’. And you know exactly how to help a person. And you guys are—you’re like family to me. I would tell them.

Only a few participants expressed negative feelings indicating that they needed more sessions with their counselor or needed to explore issues further during a session.

Most participants had positive feelings regarding the use of telemedicine to receive therapy. Compared to face-to-face counseling, 11 participants felt that telemedicine was the same, six found telemedicine to be more convenient and felt more comfortable sharing their feelings using this method of delivery, and three participants preferred face-to-face counseling.

One participant noted that:

Telemedicine is just talking to the person on the other side of the string. It seems a little easier than talking to a person that’s sitting right across from you.

Another participant, when asked about telemedicine noted:

Oh, I enjoy it. I enjoy it. It’s just like you all in the same room with me.

One participant indicated that they would not use it again for counseling, stating:

It was a little bit different. It’s all good, but I think I still prefer the—in the room with me. I just, I guess, old fashioned. I don’t know, but it just seems like you got a better relationship, closer, touchy-feely. I mean, I’m from the old school. I guess I would prefer the doctor being in the room with me.

Viral load suppression, depression symptoms, and adherence

At baseline, 19 of 22 (86.4%) participants were virally suppressed (see Table 3). This included 10 participants randomized to CBT-AD and 9 participants randomized to ISP. At Week 24, 18 of 21 (85.7%) participants that completed the follow-up were virally suppressed (10 in CBT-AD and 8 in ISP). On average, CES-D scores decreased by 16.2 points from baseline to Week 13 (36.4 vs 20.2; ES = 1.82) and by 14 points from baseline to Week 24 (36.4 vs 22.4; ES = 1.57). Scores decreased by an average of among participants receiving CBT-AD and 14.9 among participants receiving ISP from baseline to Week 13. Both groups maintained decreases in CES-D scores from baseline to Week 24 (14 in CBT-AD and 13.8 in ISP).

Table 3.

Depressive symptoms and adherence.

Viral load suppression
(<200 copies/ml)
Total (N = 22)
CBT (N = 11)
ISP (N = 11)
Between groupsa
N (%) Effect
sizeb
N (%) Effect
sizeb
N (%) Effect
sizeb
Effect sizeb
Baseline 19 (86.4) – 10 (90.9) – 9 (8l.8) – 0.44
Week 24 18 (85.7) 0.10 l0 (90.9) 0.00 8 (80) 0.23 0.23
CES-D (0–60) M (SD) M (SD) M (SD)
Baseline 36.4 (8.9) – 37.5 (7.9) – 35.3 (l0) – 0.26
Week 13 20.2 (12.2) 1.82 19.9 (13) 1.98 20.4 (11.9) 1.66 0.31
Week 24 22.4 (12.8) 1.57 23.5 (11.1) 1.57 21.5 (15) 1.57 0.00
ART adherent
previous 2 weeksc
N (%) N (%) N (%)
Baseline 17 (77.3)d – 9 (81.8)g – 8 (72.7)g – 0.29
Week 13 16 (84.2)e 0.34 9 (90.0)h 0.45 7 (77.8)i 0.29 0.16
Week 24 16 (76.2)f 0.07 9 (81.8)g 0.00 7 (70.0)h 0.13 0.13
Raw Wisepill M (SD) M (SD) M (SD)
Baseline 71.1 (33.1)f 89.6 (14.4) 50.7 (36.3)
Week 13 70.7 (32.5)e 81.4 (30.2) 58.7 (32.3)
Week 24 53.1 (41)j 55.4 (46.1) 50 (37)
Wisepill + self-report M (SD) M (SD) M (SD)
Baseline 89.6 (21.2) 94.8 (13.2) 84.4 (26.7)
Week 13 93.5 (21.5) 89.6 (30) 97.4 (5.8)
Week 24 91.8 (22.4) 87 (30.3) 97.1 (6)

CBT: cognitive behavioral therapy; ISP: information and supportive psychotherapy; CES-D: Center for Epidemiological Studies Depression Scale; ART: antiretroviral therapy.

Percentages vary depending on the total number of participants who completed the assessment.

a

Cross-sectional between-group differences at baseline, differences in change at 13 and 24 weeks.

b

Cohen’s d for numerical variables, using pooled baseline SD; and d-equivalent for binary variables. Baseline is the reference.

c

Participants who reported not missing a dose of medication within the previous 2 weeks on the AIDS Clinical Trial Group (ACTG) survey question: “When was the last time you missed taking any of your medications?”

d

N = 22.

e

N = 19.

f

N = 21.

g

N = 11.

h

N = 10.

i

N = 9.

j

N = 14.

The majority of the participants (17 of 22; 77.3%) reported complete adherence (not missing a dose of ART within the previous 2 weeks) using the ACTG at baseline. Overall, 16 of 19 (84.2%) at 3 months and 16 of 21 (76.2%) at 6 months reported not missing a dose again. In the CBT-AD group, this included 9 of 10 participants at 3 months and 9 of 11 participants at 6 months; in ISP, this included 7 of 9 at 3 months and 7 of 10 at 6 months. Raw Wisepill data indicated mean adherence of 71.1 percent at baseline, 70.7 percent at Week 13, and 53.1 percent at Week 24. After adjustments for self-reported behavior were made, the Wisepill indicated an average adherence of 89.6 percent at baseline, 93.5 percent at Week 13, and 91.8 percent at Week 24.

Discussion

The current randomized pilot trial demonstrated the feasibility and acceptability of implementing CBT-AD for depression treatment via videoconferencing among AA WLWH in the rural South. Feasibility was demonstrated by successful intervention completion and high retention in the study. Most participants (20 of 22) completed the recommended 10–12 intervention sessions, with two completing 9 sessions in total. Retention in the study was very high; all except one participant completed the 6-month follow-up visit. The high participation and retention rates in the study suggest that telemedicine-administered therapy is feasible in this population.

Acceptability of the intervention, assessed both quantitatively and qualitatively, revealed high satisfaction with intervention components, including depression counseling, HIV treatment adherence counseling, and mode of delivery (i.e. telemedicine). Participants reported positive perceptions of the telemedicine-administered sessions, including talking to the counselor, clarifying life problems, and the intervention providing useful tools. Most of the participants indicated that telemedicine-administered counseling is comparable to face-to-face counseling, with some indicating that it was more convenient, and only one participant indicating that she prefers face-to-face delivery. These results indicate that telemedicine can overcome barriers to care among AA WLWH living in the rural South who are particularly vulnerable to structural barriers of care, including transportation barriers, distance to care, and healthcare provider shortage (Moneyham et al., 2010).

While this study is the first to demonstrate the feasibility and acceptability of telemedicine-administered CBT-AD among AA WLWH, it supports findings from multiple trials by Safren et al. (2009, 2016, 2012). The feasibility and efficacy of delivering CBT-AD was first demonstrated in a majority White, non-Hispanic men who have sex with men (MSM) population (Safren et al., 2009). Participants who received between 10 and 12 CBT-AD sessions in addition to enhanced treatment as usual had better improvement in adherence and depression at 3 months compared to participants who only received enhanced treatment as usual. These improvements in adherence and depression were sustained at 6 months and 12 months.

Furthermore, Himelhoch et al. (2011) demonstrated the feasibility and acceptability of an 11-session telephone-based CBT intervention which resulted in reduced depression symptoms in a low-income, urban, majority female AA adult population living with HIV. The participants completed an average of nine sessions, and rated their satisfaction with the intervention very high (5.7 of 6 points).

In contrast to the two studies described above, this study demonstrates the feasibility and acceptability of a telemedicine-administered CBT intervention in a rural, socioeconomically disadvantaged population, where transportation, distance to care, Internet connectivity, and other environmental factors may limit provision of specialty care services, such as mental healthcare (Heckman et al., 1998; Kempf et al., 2010; Moneyham et al., 2010; Pellowski, 2014). While telemedicine-administered mental health interventions are widely underused, the current pilot trial demonstrated the feasibility of videoconference-administered therapy to address the mental health needs of AA WLWH in the South (Kempf et al., 2015).

In addition, this study indicates reductions in depression symptoms for participants assigned to CBT-AD and ISP. These findings are similar to other research among HIV-negative populations comparing therapeutic benefits of CBT with other psychotherapies in which the different approaches were comparable (Braun et al., 2013; Cuiipers et al., 2008; Wampold et al., 2002).

Limitations

There are several limitations in this study. First, to ensure proper usage of the videoconferencing equipment, Internet connectivity, and to maintain privacy and confidentiality which could not be reliably maintained within the homes, participants were required to travel to the clinic for therapy. However, given the high retention rate, this did not appear to act as a barrier in this study.

Second, the participants were not screened for adherence at enrollment. Consequently, adherence was fairly high at the beginning of the study, which could lead to a ceiling effect of the adherence results. In addition, when behavioral corrections were applied to the Wisepill, adherence increased on average. It is possible that nonuse of the device made participants more likely to report non-adherence, thus explaining the difference shown between the two adherence measures in this study. A larger trial is needed to test the feasibility of telemedicine-administered CBT and the Wisepill device among persons with varying adherence.

Also, because this study is a small pilot study, true randomization of groups was difficult to accomplish. We detected some demographic differences between groups; however, it is difficult to quantify the magnitude of true differences between the groups with small sample sizes. In addition to improved randomization, a larger efficacy trial with greater statistical power is needed to detect significant differences in depression and adherence among participants receiving telemedicine-administered CBT compared to those receiving other time-matched intervention strategies.

Despite a large number of women screened in as eligible using the CES-D, 16 were either not eligible or declined to participate. However, overall nonparticipation among women screened was very low (4/60) and the main reason for ineligibility was not meeting depression diagnosis criteria. Among 44 participants eligible to participate, using a CES-D cutoff of ⩾ 16, 14 did not meet the MINI criteria for a diagnosis of depression and therefore were incorrectly screened into the study. As discussed elsewhere, a higher CES-D cutoff score among WLWH in research settings may be warranted to reduce false positives (Junkins et al., 2019).

In conclusion, the current pilot feasibility trial demonstrated that telemedicine-administered CBT-AD is feasible and highly accepted among AA WLWH in rural Alabama. It suggests that telemedicine provides a unique and acceptable method of administering well-established psychotherapies such as CBT-AD, providing effective depression treatment and improving ART adherence in a largely unreached, particularly vulnerable population while breaking down barriers to care commonly faced by AA WLWH residing in the rural Southeastern United States.

Acknowledgments

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This research project was funded by National Institute of Mental Health (NIMH) R34 grant (No. R34 MH097588-01). Additional support came from the University of Alabama at Birmingham Center for AIDS Research, a National Institutes of Health (NIH)-funded program (Grant No. P30 AI027767 that was made possible by the following institutes: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, NIDDK, NIGMS, NIMHD, FIC, NIDCR, and OAR); as well as 9K24DA040489 and T32CA047888. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health.

Footnotes

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.S. receives royalties from Oxford University Press and Guilford Publications, and Humana Press for being an author on books. All other authors report no conflicts of interests.

References

  1. Ammassari A, Antinori A, Aloisi MS, et al. (2004) Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 45: 394–402. [DOI] [PubMed] [Google Scholar]
  2. Andrinopoulos K, Clum G, Murphy DA, et al. (2011) Health related quality of life and psychosocial correlates among HIV-infected adolescent and young adult women in the US. AIDS Education and Prevention 23: 367–381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Attkisson C (1982) The Client Satisfaction Questionnaire: Psychometric properties and correlations with service utilization and psychotherapy outcome. Evaluation and Program Planning 5: 233. [DOI] [PubMed] [Google Scholar]
  4. Benavides-Vaello S, Strode A and Sheeran B (2013) Using technology in the delivery of mental health and substance abuse treatment in rural communities: A review. The Journal of Behavioral Health Services & Research 40: 111–120. [DOI] [PubMed] [Google Scholar]
  5. Bhatia R, Hartman C, Kallen MA, et al. (2011) Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: Results from the steps study. AIDS and Behavior 15: 1161–1170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bing EG, Burnam MA, Longshore D, et al. (2001) Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry 58: 721–728. [DOI] [PubMed] [Google Scholar]
  7. Bouhnik AD, Preau M, Vincent E, et al. (2005) Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antiviral Therapy 10: 53–61. [PubMed] [Google Scholar]
  8. Braun SR, Gregor B and Tran US (2013) Comparing bona fide psychotherapies of depression in adults with two meta-analytical approaches. PLoS ONE 8: e68135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brody DJ, Pratt LA and Hughes JP (2018) Prevalence of depression among adults aged 20 and over: United States, 2013-2016. NCHS Data Brief 303: 1–8. [PubMed] [Google Scholar]
  10. Carrieri MP, Leport C, Protopopescu C, et al. (2006) Factors associated with nonadherence to highly active antiretroviral therapy: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. Journal of Acquired Immune Deficiency Syndromes 41: 477–485. [DOI] [PubMed] [Google Scholar]
  11. Castleberry A (2014) NVivo 10 [software program]. Version 10. QSR International; 2012. American Journal of Pharmaceutical Education 78: 25. [Google Scholar]
  12. Catz SL, Kelly JA, Bogart LM, et al. (2000) Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology: Official Journal of the Division of Health Psychology 19: 124–133. [PubMed] [Google Scholar]
  13. CDC (2010) Current depression among adults—United States, 2006 and 2008. MMWR 59: 1229–1235. [PubMed] [Google Scholar]
  14. CDC (2014) HIV surveillance report 26. Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2014-vol-26.pdf
  15. Chesney MA, Chambers DB, Ickovics JR, et al. (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. AIDS Care 12: 255–266. [DOI] [PubMed] [Google Scholar]
  16. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences (2nd edn). Hillsdale, NJ: Lawrence Erlbaum. [Google Scholar]
  17. Cook JA, Grey D, Burke J, et al. (2004) Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. American Journal of Public Health 94: 1133–1140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cuiipers P, Straten A, Andersson G, et al. (2008) Psychotherapy for depression in adults: A meta-analysis of comparative outcome studies. Journal of Consulting and Clinical Psychology 76: 909–922. [DOI] [PubMed] [Google Scholar]
  19. Dalessandro M, Conti CM, Gambi F, et al. (2007) Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. Journal of Clinical Psychopharmacology 27: 58–61. [DOI] [PubMed] [Google Scholar]
  20. Davies EB, Morriss R and Glazebrook C (2014) Computer-delivered and web-based interventions to improve depression, anxiety, and psychological well-being of university students: A systematic review and meta-analysis. Journal of Medical Internet Research 16: e130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Do AN, Rosenberg ES, Sullivan PS, et al. (2014) Excess burden of depression among HIV-infected persons receiving medical care in the United States: Data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS ONE 9: e92842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Dobkin RD, Interian A, Durland JL, et al. (2018) Personalized telemedicine for depression in Parkinson’s disease: A pilot trial. Journal of Geriatric Psychiatry and Neurology 31: 171–176. [DOI] [PubMed] [Google Scholar]
  23. Egede LE, Acierno R, Knapp RG, et al. (2015) Psychotherapy for depression in older veterans via telemedicine: A randomised, open-label, non-inferiority trial. The Lancet Psychiatry 2: 693–701. [DOI] [PubMed] [Google Scholar]
  24. Farinpour R, Miller EN, Satz P, et al. (2003) Psychosocial risk factors of HIV morbidity and mortality: Findings from the Multicenter AIDS Cohort Study (MACS). Journal of Clinical and Experimental Neuropsychology 25: 654–670. [DOI] [PubMed] [Google Scholar]
  25. Gidora H, Borycki EM and Kushniruk AW (2019) Effects of telenursing triage and advice on healthcare costs and resource use. Studies in Health Technology and Informatics 257: 133–139. [PubMed] [Google Scholar]
  26. Gonzalez JS, Batchelder AW, Psaros C, et al. (2011) Depression and HIV/AIDS treatment nonadherence: A review and meta-analysis. Journal of Acquired Immune Deficiency Syndromes 58: 181–187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Heckman TG, Somlai AM, Peters J, et al. (1998) Barriers to care among persons living with HIV/AIDS in urban and rural areas. AIDS Care 10: 365–375. [DOI] [PubMed] [Google Scholar]
  28. Himelhoch S, Mohr D, Maxfield J, et al. (2011) Feasibility of telephone-based cognitive behavioral therapy targeting major depression among urban dwelling African-American people with co-occurring HIV. Psychology, Health & Medicine 16: 156–165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hodder SL, Justman J, Hughes JP, et al. (2013) HIV acquisition among women from selected areas of the United States: A cohort study. Annals of Internal Medicine 158: 10–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Junkins A, Azuero A, Ott C, et al. (2019) Center for Epidemiological Studies-Depression Scale: Evaluation of a new cutoff score for women living with HIV. AIDS Patient Care and STDs 33: 343–345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kempf MC, Huang CH, Savage R, et al. (2015) Technology-delivered mental health interventions for people living with HIV/AIDS (PLWHA): A review of recent advances. Current HIV/AIDS Reports 12: 472–480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kempf MC, McLeod J, Boehme AK, et al. (2010) A qualitative study of the barriers and facilitators to retention-in-care among HIV-positive women in the rural southeastern United States: Implications for targeted interventions. AIDS Patient Care and STDs 24: 515–520. [DOI] [PubMed] [Google Scholar]
  33. Leon AC, Davis LL and Kraemer HC (2011) The role and interpretation of pilot studies in clinical research. Journal of Psychiatric Research 45: 626–629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lorentz MM (2008) Telenursing and home healthcare. the many facets of technology. Home Healthcare Nurse 26: 237–243. [DOI] [PubMed] [Google Scholar]
  35. Moneyham L, McLeod J, Boehme A, et al. (2010) Perceived barriers to HIV care among HIV-infected women in the deep South. Journal of the Association of Nurses in AIDS Care 21: 467–477. [DOI] [PubMed] [Google Scholar]
  36. Mugavero M, Ostermann J, Whetten K, et al. (2006) Barriers to antiretroviral adherence: The importance of depression, abuse, and other traumatic events. AIDS Patient Care and STDs 20: 418–428. [DOI] [PubMed] [Google Scholar]
  37. Murphy DA, Wilson CM, Durako SJ, et al. (2001) Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 13: 27–40. [DOI] [PubMed] [Google Scholar]
  38. Nair U, Armfield NR, Chatfield MD, et al. (2018) The effectiveness of telemedicine interventions to address maternal depression: A systematic review and meta-analysis. Journal of Telemedicine and Telecare 24: 639–650. [DOI] [PubMed] [Google Scholar]
  39. Nanni MG, Caruso R, Mitchell AJ, et al. (2015) Depression in HIV infected patients: A review. Current Psychiatry Reports 17: 530. [DOI] [PubMed] [Google Scholar]
  40. Paterson DL, Swindells S, Mohr J, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133: 21–30. [DOI] [PubMed] [Google Scholar]
  41. Pellowski JA (2014) Barriers to care for rural people living with HIV: A review of domestic research and health care models. The Journal of the Association of Nurses in AIDS Care 24: 422–437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Pence BW, Miller WC, Whetten K, et al. (2006) Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. Journal of Acquired Immune Deficiency Syndromes 42: 298–306. [DOI] [PubMed] [Google Scholar]
  43. Rabkin JG (2008) HIV and depression: 2008 review and update. Current HIV/AIDS Reports 5: 163–171. [DOI] [PubMed] [Google Scholar]
  44. Radloff LS (1977) The CES-D Scale: A Self-Report Depression Scale for research in the general population. Applied Psychological Measurement 1: 385–401. [Google Scholar]
  45. Reif S, Geonnotti KL and Whetten K (2006) HIV infection and AIDS in the deep South. American Journal of Public Health 96: 970–973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Roberts KJ and Mann T (2000) Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care 12: 377–386. [DOI] [PubMed] [Google Scholar]
  47. Robertson K, Bayon C, Molina JM, et al. (2014) Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care 26: 1555–1561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Rohland BM (2001) Telepsychiatry in the heartland: If we build it, will they come? Community Mental Health Journal 37: 449–459. [DOI] [PubMed] [Google Scholar]
  49. Rosenthal R and Rubin DB (2003) R-equivalent: A simple effect size indicator. Psychological Methods 8: 492–496. [DOI] [PubMed] [Google Scholar]
  50. Rush KL, Howlett L, Munro A, et al. (2018) Videoconference compared to telephone in healthcare delivery: A systematic review. International Journal of Medical Informatics 118: 44–53. [DOI] [PubMed] [Google Scholar]
  51. Safren SA, Bedoya CA, O’Cleirigh C, et al. (2016) Cognitive behavioural therapy for adherence and depression in patients with HIV: A threearm randomised controlled trial. Lancet HIV 3: e529–538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Safren SA, O’Cleirigh C, Tan JY, et al. (2009) A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychology: Official Journal of the Division of Health Psychology 28: 1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Safren SA, O’Cleirigh CM, Bullis JR, et al. (2012) Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: A randomized controlled trial. Journal of Consulting and Clinical Psychology 80: 404–415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Safren SA, Otto M and Worth J (1999) Life steps: Applying cognitive behavioral therapy to HIV medication adherence. Cognitive and Behavioral Practice 6: 332–341. [Google Scholar]
  55. Schumacher JE, McCullumsmith C, Mugavero MJ, et al. (2013) Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment. AIDS and Behavior 17: 2781–2791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Sherr L, Clucas C, Harding R, et al. (2011) HIV and depression—A systematic review of interventions. Psychology, Health & Medicine 16: 493–527. [DOI] [PubMed] [Google Scholar]
  57. Stringer KL, Azuero A, Ott C, et al. (2019) Feasibility and acceptability of real-time antiretroviral adherence monitoring among depressed women living with HIV in the deep South of the US. AIDS and Behavior 23: 1306–1314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Swinton JJ, Robinson WD and Bischoff RJ (2009) Telehealth and rural depression: Physician and patient perspectives. Families, Systems & Health: The Journal of Collaborative Family Healthcare 27: 172–182. [DOI] [PubMed] [Google Scholar]
  59. Turner BJ, Laine C, Cosler L, et al. (2003) Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. Journal of General Internal Medicine 18: 248–257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Vandelanotte C and De Bourdeaudhuji I (2003) Acceptability and feasibility of a computer-tailored physical activity intervention using stages of change: Project FAITH. Health Education Research 18: 304–317. [DOI] [PubMed] [Google Scholar]
  61. Vyavaharkar M, Moneyham L, Murdaugh C, et al. (2012) Factors associated with quality of life among rural women with HIV disease. AIDS and Behavior 16: 295–303. [DOI] [PubMed] [Google Scholar]
  62. Wampold BE, Minami T, Baskin TW, et al. (2002) A meta-(re)analysis of the effects of cognitive therapy versus “other therapies” for depression. Journal of Affective Disorders 68: 159–165. [DOI] [PubMed] [Google Scholar]
  63. Xu T, Pujara S, Sutton S, et al. (2018) Telemedicine in the management of type 1 diabetes. Preventing Chronic Disease 15: E13. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES